arrow
N

Nadine Abdallah

Mayo Clinic
H指数:20
被引数:1,462

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Multicenter characterization of enterocolitis associated with BCMA-directed CAR T cell therapy

多中心研究BCMA靶向CAR T细胞疗法相关的肠结肠炎特征

2026-11-190
OA
Caregiver support in patients with plasma cell dyscrasias: A novel single‐item pilot measure of caregiver availability: Results from a survey of >1000 patients

血浆细胞异常患者的照护者支持:一种新型的单项目照护者可用性试点测量方法:来自对1000多名患者调查的结果

2026-11-130
OAAI
Survival trends in Waldenström macroglobulinemia and comparison of outcomes with the general United States population

华氏巨球蛋白血症的生存趋势及与全美普通人群结局的比较

Leukemia
IF13.4
2026-11-120
PRE
Biomarkers of cellular senescence and their association with frailty, clinical outcomes, and survival in multiple myeloma

细胞衰老的生物标志物及其与多发性骨髓瘤中虚弱、临床结局和生存期的关联

2026-10-300
OAAI
Chromosome 1q Gain Defines a Plasma Cell–Dominant Adverse-Risk Subtype in AL Amyloidosis With Inferior Long-Term Survival

1q染色体增益定义了AL淀粉样变性中一种浆细胞占优势的不良风险亚型,其长期生存率较差

2026-08-260
PRE
Prophylactic dexamethasone at the time of absolute lymphocyte expansion does not mitigate risk or event-free survival for immune effector cell associated delayed neurotoxicity

预防性地塞米松在绝对淋巴细胞扩增时并不能减轻与免疫效应细胞相关的迟发性神经毒性的风险或无事件生存期

2026-08-100
OA
Self-Reported Geriatric Impairments and Treatment Toxicity in Older Patients with Multiple Myeloma–A Single Center Prospective Study

老年多发性骨髓瘤患者自报的老年功能损害和治疗毒性的单中心前瞻性研究

2026-07-300
OA
Predictors of post-transplant measurable residual disease negativity and impact on clinical outcomes in multiple myeloma

移植后可测量残留病灶阴性的预测因素及其对多发性骨髓瘤临床结局的影响

2026-07-290
OA
Cytogenetics-based clinical trajectories in patients with MRD negativity post autologous transplant for multiple myeloma
Leukemia
IF13.4
2026-07-210
PRE
Clinical Course, Risk Factors, and Therapeutic Response in Multiple Myeloma with Central Nervous System Involvement

中枢神经系统受累的多发性骨髓瘤的临床病程、危险因素和治疗效果

2026-06-260
OA
Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple Myeloma

接受Ciltacabtagene-Autoleucel治疗的复发/难治性多发性骨髓瘤患者的早期治疗失败

2026-06-250
PRE
Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell Leukemia

原发性浆细胞白血病患者首次进展后的进展模式与临床结局

2026-06-030
PRE
Management of hematological toxicities after BCMA-directed CAR-T cell therapy

BCMA靶向CAR-T细胞疗法后的血液学毒性管理

2026-03-300
OAAI
Elevated non-clonal bone marrow plasma cell fraction at diagnosis is associated with improved outcomes in multiple myeloma

诊断时升高的非克隆性骨髓浆细胞分数与多发性骨髓瘤的预后改善相关

2026-01-030
OAAI
Impact of t(11;14) primary cytogenetic abnormality and the cumulative effect of multiple high-risk cytogenetics at diagnosis on the outcomes of patients with primary plasma cell leukemia

t(11;14)初发细胞遗传学异常及诊断时多种高危细胞遗传学累积效应对原发性浆细胞白血病预后的影响

2025-12-270
OAAI
AL Amyloidosis: A Real-World Experience with CAR-T Cell Therapy

AL淀粉样变性:CAR-T细胞疗法的真实世界经验

2025-10-170
OAAI
Clinical Characteristics, Treatment Responses and Outcomes of Light Chain Multiple Myeloma

轻链型多发性骨髓瘤的临床特征、治疗反应及预后

2025-10-040
PRE
Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomes

自体干细胞移植时处于S期的残留克隆性浆细胞对临床结局的影响

2025-09-290
OAAI